Roche dumps its PhI­II PI3K ef­fort on taselis­ib af­ter re­searchers track poor sur­vival edge, harsh side ef­fects for breast can­cer

CHICA­GO — You can write off an­oth­er PI3K drug.

Roche has de­cid­ed to scrap its con­tender taselis­ib af­ter in­ves­ti­ga­tors re­port­ed a slight, 2-month pro­gres­sion-free sur­vival ad­van­tage for the drug — along with a sketchy safe­ty pro­file com­mon to the class — com­bined with ful­ves­trant hor­mone ther­a­py in a Phase III study of metasta­t­ic breast can­cer.

Here’s what Roche had to say:

The mag­ni­tude of ben­e­fit ob­served in SAND­PIPER isn’t as strong as we had hoped for and, giv­en the chal­leng­ing safe­ty pro­file of this com­bi­na­tion and the cur­rent clin­i­cal land­scape, we will not be pur­su­ing an FDA sub­mis­sion for taselis­ib based on the da­ta pre­sent­ed at AS­CO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER